WallStSmart
KPTI

Karyopharm Therapeutics Inc

NASDAQ: KPTI · HEALTHCARE · BIOTECHNOLOGY

$8.31
-1.07% today

Updated 2026-04-30

Market cap
$195.22M
P/E ratio
P/S ratio
1.34x
EPS (TTM)
$-17.80
Dividend yield
52W range
$4 – $11
Volume
1.0M

Karyopharm Therapeutics Inc (KPTI) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-66.6%
Last 4 quarters
Revenue YoY growth
+11.6%
Most recent quarter
EPS YoY growth
-58.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+4.4%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+16.4%
2026-02-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-12$-5.69-2577.6%$7.37$8.58+16.4%
2025-11-05$-3.82-72.9%$5.65$5.22-7.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.21$-5.69-2577.6%$34.08M+11.6%
2025-09-30$-2.21$-3.82-72.9%$44.04M+13.6%
2025-06-30$-3.91$-4.07-4.1%$37.93M-11.4%
2025-03-31$-3.09$-2.77+10.4%$30.02M-9.4%
2024-12-31$-4.03$-3.60+10.7%$30.54M-9.5%
2024-09-30$-3.92$-3.90+0.5%$38.78M+7.7%
2024-06-30$-0.30$0.15+150.0%$42.79M+13.9%
2024-03-31$-0.33$-0.32+3.0%$33.13M-14.4%
2023-12-31$-0.31$-0.36-16.1%$33.75M
2023-09-30$-0.28$-0.30-7.1%$36.01M
2023-06-30$-0.34$-0.29+14.7%$37.58M
2023-03-31$-0.37$-0.30+18.9%$38.70M

Frequently asked questions

Has Karyopharm Therapeutics Inc beaten earnings estimates?
Karyopharm Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -66.6% over the last 4 quarters.
How does KPTI stock react to earnings?
KPTI stock has moved an average of +4.4% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Karyopharm Therapeutics Inc's revenue growth rate?
Karyopharm Therapeutics Inc reported year-over-year revenue growth of +11.6% in its most recent quarter, with EPS growing -58.1% year-over-year.